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Abstract Polyomavirus-associated nephropathy is diag-
nosed in 2–8% of pediatric renal transplants and often
precedes renal allograft dysfunction. Without intervention,
however, significant graft dysfunction is observed in more
than 50% of cases, although progressive early graft loss is
reported in only three of 32 (9%) of cases. No specific
treatment is available, but early decrease in immunosup-
pression is followed by declining human polyomavirus type
1 (BK virus) replication and improved outcome. The data
suggest differences between pediatric and adult kidney
transplantation. Possibly, pediatric patients might be able to
mount a more vigorous BK virus-specific immune response
than adult patients under similar modulation of immuno-
suppression. Also the role of cidofovir and leflunomide is
still unresolved in pediatric patients. Larger prospective
trials are needed to better define the impact of BK virus
immunity for replication and disease as well as the role of
reducing immunosuppression with or without cidofovir or
leflunomide in pediatric transplant patients.
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Abbreviations
AZA azathioprine
BKV BK virus
CAN chronic allograft nephropathy
CMV cytomegalovirus
Creat creatinine (μM/liter)
CyA cyclosporine A
DD deceased donor
ELISA enzyme-linked immunosorbent assay
EM electron microscopy
HIA hemagglutination inhibition assay
IF indirect immunofluorescence
MMF mycophenolate mofetil
LRD living related donor
PCR polymerase chain reaction
PVAN polyomavirus-associated nephropathy
PRED prednisone
RED restriction enzyme digestion
SV40 simian virus 40
SRL sirolimus
TAC tacrolimus
Introduction
Kidney transplantation is the treatment of choice for
children with end-stage renal disease, showing improving
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organ and patient survival over the past decade [1]. Part of
this success is based on falling rates of acute allograft
rejection, albeit at the expense of a rising number of
infectious complications posttransplant [2]. In this setting,
polyomavirus-associated nephropathy (PVAN) has emerged
as one of the most formidable challenges [3–5]. PVAN has
been initially described in adult patients [6, 7], and most
data has been obtained from this patient population [8]. In
fact, older recipient age of >50 years has been identified in
some studies as an independent risk factor for PVAN [9].
However, PVAN also occurs in pediatric patients. For the
purposes of this review, we will focus on human poly-
omavirus type 1 [BK virus (BKV)] infection, replication,
and disease in pediatric kidney transplant recipients.
BKV in the general population
Natural transmission of the BKV presumably occurs by
respiratory or oral-enteric routes in children at a peak age of
2–5 years. Although no specific symptoms or signs have
been identified, primary BKV replication may not necessar-
ily be asymptomatic but in fact go unnoticed as a “flu-like”
disease. Subsequently, BKV establishes nonreplicative,
latent infection in renal tubular epithelial cells and
uroepithelium [10]. The significance of detecting BKV in
placental tissues or in cerebrospinal fluid of children with
symptoms or signs of central nervous system disease
requires further study [11]. Antibodies to BKV are
commonly seen in 60–90% healthy adults, with most
children being BKV seropositive by age 10 years [12,
13]. Differences have been observed between the conven-
tional hemagglutination inhibition assay and the more
sensitive enzyme immunoassays (EIA) techniques using
BKV virus-like particles.
Pediatric studies postrenal transplantation
Table 1 details relevant data regarding prevalence of BKV
infection, replication, and disease in the pediatric renal
transplant population. Alexander et al. [14] screened 52
pediatric renal transplant recipients for polyomavirus
replication. BKV was detected in the urine of ten patients
(19%), in plasma of seven (13.4%), and in allograft
biopsies as PVAN in four (7.7%). Evaluation of BKV
viruria by electron microscopy (EM) typically requires a
viral concentration of 106–107 particles/ml and is therefore
not as sensitive as polymerase chain reaction (PCR). This
limited sensitivity may account for two cases of BKV
viremia without concomitant viruria, or alternatively point
to de novo infection in these patients. Ginevri et al. [15]
conducted a prospective analysis of 100 pediatric renal
transplant patents, with detectable BKV antibody in 70% at
time of transplantation. By nested PCR assays, they found
BKV viruria in 26%, BKV viremia in 5% of cases, three of
whom progressed to BKV nephropathy during follow-up.
In this study, mycophenolate mofetil (MMF) at baseline
Table 1 Pediatric studies evaluating recipient human polyomavirus type 1 (BKV) antibody status, viruria, viremia, and/or nephropathy
Authors Study
methodology
Pt.
number
Antibody
detectable
Method
(cutoff titre)
Viruria
(BKV)
Method Viremia
(BKV)
Method PVAN
(BKV)
Alexander
et al. [14]
Retrospective KT 52 N/A 19% EM * 13% PCR + RED 7.7%
Ginevri
et al. [15]
Retrospective KT 100 70% HIA
(pos≥1:40)
26% Nested PCR 5% Nested PCR 3%
Haysom
et al. [16]
Prospective KT
case control
(age matched 1:1)
18 56%
(39%)
IF IgG
(pos≥1:10)
33%
(39%)
PCR +
hybridization
6% (0%) PCR +
hybridization
0%
Herman
et al. [17]
Prospective 46 N/A 20 Quantitative
PCR
11% Quantitative
PCR
4.3%
Hymes
et al. [36]
Prospective 122 N/A N/A 16% Quantitative
PCR
6.6%
Muller
et al. [37]
Cross-sectional KT,
controls (KD, n=35)
(KDI, n=7)
38 N/A 18%
(KD 0%)
(KDI 0%)
Nested PCR
+ RED
5% (KD 0%)
(KDI 14%)
Nested PCR 3%
Smith
et al. [26]
Retrospective,
histology workup
for PVAN
192 N/A (subgroup
of PVAN)
BKV VLP
(17%)
N/A Quantitative
PCR (100%)
N/A Quantitative
PCR (100%)
3.5%
PVAN polyomavirus-associated nephropathy, N/A not available, EM electron microscopy, PCR polymerase chain reaction, RED restriction enzyme
digestion, KT kidney transplantation, HIA hemagglutination inhibition assay, IF indirect immunofluorescence (cell culture conditions not
indicated), KD kidney disease, KDI kidney disease treated with immunosuppression, VLP virus-like particles, Pt patient, * requires > 106
particles per ml and does not distinguish between BKV and JC virus
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was associated with BKV nephropathy, whereas calcineurin
inhibitor choice [tacrolimus vs. cyclosporin A (CyA)] and
basiliximab induction were not associated with viruria,
viremia, or nephropathy [15]. The role of immunosuppres-
sion for BKV replication was also demonstrated in a
prospective case-control study of 18 Australian pediatric
renal transplants with a seropositivity of 56% for BKV IgG,
of whom 33% developed viruria as measured by PCR
compared with no viruria in the age matched controls that
had 39% seropositivity [16]. Herman et al. [17] found
similar prevalence rates for BKV viruria (20%), BKV
viremia (11%), and PVAN (4.3 %) in 46 patients followed
prospectively. Of note, all of these children received
antibody induction therapy in contrast to only 18% and
22% of patients studied by Ginevri et al. [15] and Haysom
et al. [16], respectively (Table 2). Although more specific
studies are needed, the data suggests that induction therapy
does not influence prevalence of BKV replication and
disease in the pediatric renal transplant population similar
to reports in adult kidney transplantation [18], but differ-
ences between depleting and nondepleting antibodies and
the small sample sizes in these studies should be acknowl-
edged. The role of different calcineurin inhibitors cannot be
answered conclusively, as no randomized controlled trials
were performed. As can be gathered from Table 2, all
combinations can be found among the cases of PVAN in
children.
Table 3 summarizes 32 cases of PVAN in pediatrics and
the outcomes obtained in individuals younger than 20 years
of age. The time point of first diagnosis of PVAN varies
considerably from 1 to 48 months after transplant. It is
noted that only three allografts (13%) were lost in this
series, with the majority stabilizing with a reduction of
immunosuppressive treatment. There was no uniform
strategy for how to reduce immunosuppression as to drug
switching, single drug reduction, and reduction of all
immunosuppressants. As a common scheme, however, a
30% reduction in calcineurin-inhibitor dosing, a 50%
reduction in antiproliferative drug dosing, and tapering of
steroids to <10 mg has been common practice. Cidofovir
was used in 16/32 patients (Table 3) and was associated
with a favorable outcome in 13 cases (81%), which was not
significantly different from that observed in patients treated
solely with reduced immunosuppression of 11/15 (73%).
The role of leflunomide cannot be evaluated from a single
case with subsequent graft loss. The mechanism of action
of leflunomide and cidofovir is under investigation (for
review, see [19, 20]).
Data from PVAN cases in adults suggest that steroids
may be a risk factor for BKV replication and disease, but
the role of reducing steroids as part of reducing immuno-
suppression is not clear. It is important to note that in most
patients, BKV viremia will only start to decline for >1 log
after 4–8 weeks. Breakthrough rejection was seen, and
often, intense treatment of rejection preceded the recogni-
tion of PVAN, as has been reported in some adult studies
[6, 18, 21].
Interstitial infiltrates at the time of diagnosis or following
the reduction of immunosuppression in cases with PVAN
are difficult to distinguish from acute rejection episodes.
BKV-specific immune reconstitution has been associated
with declining plasma BKV loads in the peripheral blood
[22], which may follow the homing of BKV-specific
lymphocytes to the sites of replication in the renal allograft.
Considerable controversies exist over the role of adjunct
diagnostic markers and the risk/benefit of short courses of
steroids [8, 23]. Recent studies applying expression
profiling [24] and urine proteomics [25] suggest new
diagnostic tools, which are, however, faced with consider-
able data scatter, and will have to stand the test of
prospective studies and the challenge of clinical practice.
Up to now, the data is not sufficient to determine
whether or not primary BKV replication in seronegative
kidney transplant recipients had a worse outcome compared
with seropositive patients with secondary BKV replication.
It can be speculated that patients with no or little BKV-
specific memory compartment may need more time to
mount sufficient control to terminate BKV replication. Only
Table 2 Patient-specific data for pediatric studies evaluating recipient human polyomavirus type 1 (BKV) antibody status, viruria, viremia, and/or
nephropathy
Authors Induction therapy
% antilymphocyte/% basiliximab
PRED (%) CyA (%) TAC (%) RAPA (%) MMF (%) AZA (%) DD/LRD
(%)/(%)
Alexander et al. [14] N/A 100 11 87 16 65 15 N/A
Ginevri et al. [15] 0/18 100 79 21 0 22 N/A 95/5
Haysom et al. [16] 0/22 100 61 39 0 56 N/A 83/17
Herman et al. [17] 100 (either) 100 54 41 N/A 28 63 78/22
Hymes et al. [36] 0/100 100 12.5 87.5 50 50 12.5 N/A
Muller et al. [37] 8/0 100 61 39 0 71 0 61/39
PRED prednisone, CyA cyclosporine, TAC tacrolimus, RAPA rapamycin, MMF mycophenolate mofetil, AZA azathioprine, DD deceased donor,
LRD living related donor, N/A not available
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three children were identified as 5 years of age or younger.
A retrospective study of 173 pediatric renal transplant
patients had similar results, with six patients (3.5%) having
PVAN a median of 15 months posttransplantation with
functioning grafts during follow-up of a median of
28 months [26]. This study noted in the patients with
PVAN that all had viruria (median = 6.1 million copies/ml),
all had viremia (median = 21,000 copies/ml), and recipient
seronegative status for BKV using the sensitive BKV virus-
like particle enzyme-linked immunosorbent assay (ELISA)
was a risk factor for developing PVAN [26].
BKV load in urine and blood has been found to be a
helpful marker in identifying pediatric kidney transplant
patients at risk of PVAN. Also, the course of plasma BKV
loads has been used as a surrogate marker of allograft
involvement, according to the results in adult patients [18,
27, 28]. At this point, however, no comparable pediatric data
are available indicating that a plasma BKV load threshold of
>10,000 copies/ml for >3 weeks is associated with a 93%
sensitivity and specificity of histologically defined, e.g.,
definitive, PVAN. Even in adult patients, there are only few
prospective studies addressing this issue. In a prospective
study from the University of Maryland Transplant Center in
Baltimore, MD, USA. Hirsch together with Drachenberg and
Ramos reported a cut-off of 10,000 copies/ml was associated
with a sensitivity of 68% and a specificity of 95% [29]. The
lower sensitivity might be explained by a false negative
biopsy result that, in retrospective studies, has been
estimated to range from 10% to 30% [30] and might be
higher in the prospective setting. Similar data for urine viral
loads are lacking, and, despite the long-known relationship
of urine viral loads being approximately 1,000-fold higher
than plasma viral loads [31], no significant viruria threshold
has been established. Thus, viruria currently serves as a very
sensitive marker to exclude BKV replication but in the
positive cases should be confirmed by viremia and eventu-
ally biopsy (Fig. 1).
Oncogenic potential
The transforming potential of BKV infection has been
noted early both in nonnatural experimental hosts and in in
vitro tissue culture models. In these models BKV late gene
expression/host cell lysis does not occur and the early gene
mediated subversion of protooncogene and tumor-suppres-
sor gene functions, particularly by large T-antigen function
[4]. BKV-mediated oncogenicity is postulated in a report of
a child with an adenocarcinoma of the donor renal allograft
pelvis following PVAN virus allograft nephropathy, with
regression of secondary tumors and a return to good health
after removal of the primary tumor and cessation of
immunosuppression [32]. Curiously, one of the pediatric
BKVN patients reported by Vats et al. [33] presented with
an echogenic mass that resolved with immunosuppression
reduction and treatment with cidofovir. Rubio et al. [34]
reported a child with PVAN and Epstein-Barr virus (EBV)-
related posttransplant lymphoproliferative disease.
Implications for screening programs in pediatrics
Although PVAN is generally thought to be the result of
reactivation of BKV latent in renal tubules, it may represent a
primary infection in younger children. This patient group may
respond differently than patients with reactivation of latent
virus from the transplanted kidney. Table 4 outlines pediatric
patients who may be at higher risk of PVAN. These issues
may become key considerations in children when developing
a screening program, as both Ginevri et al. [15] and Smith et
al. [26] noted recipient seronegativity for BKV antibody was
significantly associated with risk of developing PVAN. In
these pediatric patients, BKV viruria (six of six evaluated)
and BKV viremia (five of five evaluated) preceded PVAN, as
reported in adult patients by Hirsch et al. [18]. Alexander et
al. [14] described two exceptions of viruria predating viremia,
although this group used a less sensitive assessment of BKV
viruria (EM for BKV) in comparison with PCR techniques.
Herman et al. [17] did find correlation of BKV viremia with
BKV viruria load and noted viruria predated viremia by a few
weeks. However, as seropositive recipients may still develop
BKV replication and disease, and more comprehensive data
are lacking, it is currently not recommended to universally
screen donors and pediatric transplant recipients for BKV
serostatus but for BKV replication.
Summary and clinical relevance
PVAN affects 2–8% of pediatric renal transplants and often
precedes renal allograft dysfunction. Significant graft
dysfunction is observed in more than 50% of cases,
although progressive early graft loss is reported in only
three of 32 (9%) of cases. These estimates may reflect a
reporting bias and are clearly limited by the lack of larger
studies with sufficient follow-up. However, it cannot be
excluded that pediatric patients might be able to mount a
more vigorous BKV-specific immune response than adult
patients under similar modes of immunosuppression. No
specific treatment is available, although an improvement is
often noted by a judicious decrease in immunosuppression.
Dosing strategies to improve the efficacy and minimize the
toxicity of cidofovir are emerging, as discussed by Araya et
al. [35]. Clearly, randomized controlled trials are needed to
prove any benefit of cidofovir in addition to reduced
immunosuppression.
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• allograft 
dysfunction 
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• Confirmed in <4 wks 
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Immunosuppression 
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• Electron microscopy 
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Viremia
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viruria
• q2 wks 
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Allograft 
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(Acute rejection 
drug toxicity 
underlying disease) 
Negative 
“resolved 
• Cidofovir? 
• Leflunomide?
Fig. 1 Screening and treating
human polyomavirus type 1
(BKV) replication and disease in
kidney transplant
Table 4 Pediatric renal transplant risk factors for polyomavirus-associated nephropathy (PVAN)
Positive BKV viruria BKV antibody mismatch Recipient BKV antibody-negative status Reduced BKV-specific cellular immunity
Decoy cells D+ / R– R– and < 5 years of age Lack of BKV-specific interferon-γ-secreting
lymphocytes in peripheral blood
mononuclear cells
Electron microscopy
Quantitative PCR
BKV human polyomavirus type 1, PCR polymerase chain reaction, D+ donor seropositive, R– recipient seronegative
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Understanding the role of BKV in transmission, target
organ, risk factors, time frame of reactivation, and treatment
options will be essential to improving transplant results in
terms of patient morbidity, mortality, and graft survival.
Understanding the contributions of viral infection and
immune regulation in the pediatric renal transplant popula-
tion would allow development of successful long-term
strategies to minimize immunosuppressant drugs, viral
injury, and rejection risk to pediatric patients with BKV
infection. Until then, screening pediatric transplant patients
for BKV replication by quantitative assays at least 3
monthly for the first 2 years and every time a biopsy is
taken for cause or for surveillance will help to improve
diagnosis and provide rationales for optimizing immuno-
suppressive treatment (Fig. 1).
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